870 filings
Page 12 of 44
8-K
DRRX
Durect Corp
2 Oct 19
DURECT Announces FDA Advisory Committee Meeting to Review POSIMIRĀ® for the Treatment of Post-Surgical Pain
3:30pm
8-K
DRRX
Durect Corp
17 Sep 19
DURECT Announces Positive Data from its Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis
10:47am
8-K
DRRX
Durect Corp
9 Sep 19
Other Events
1:36pm
SC 13G
Bleichroeder LP
5 Sep 19
Durect Corp
8:12pm
3
Bleichroeder LP
5 Sep 19
Initial statement of insider ownership
2:43pm
4
First Eagle Holdings, Inc.
4 Sep 19
Change in insider ownership
5:50pm
SC 13G/A
First Eagle Investment Management, LLC
4 Sep 19
Durect Corp
5:27pm
8-K
DRRX
Durect Corp
13 Aug 19
Other Events
4:33pm
10-Q
2019 Q2
DRRX
Durect Corp
Quarterly report
2 Aug 19
2:31pm
8-K
DRRX
Durect Corp
1 Aug 19
DURECT Corporation Announces Second Quarter 2019 Financial Results and Update of Programs
4:15pm
8-K
DRRX
Durect Corp
23 Jul 19
DURECT and Gilead Enter into License Agreement for Long-Acting Injectable HIV Investigational Product
2:08pm
8-K
DRRX
Durect Corp
17 Jul 19
DURECT Announces that the FDA Agreed to File the Full Response to the POSIMIRĀ® Complete Response Letter as a Complete Class 2 Resubmission
8:30am
SC 13G/A
BLK
Blackrock Inc.
10 Jul 19
Durect Corp
4:25pm
8-K
DRRX
Durect Corp
27 Jun 19
DURECT Announces Submission to FDA of a Full Response to the POSIMIRĀ® Complete Response Letter
12:45pm
8-K
DRRX
Durect Corp
25 Jun 19
DURECT Receives Approval from Nasdaq for Transfer of Listing to Nasdaq Capital Market
4:45pm
4
First Eagle Holdings, Inc.
24 Jun 19
Change in insider ownership
2:12pm
424B5
DRRX
Durect Corp
21 Jun 19
Prospectus supplement for primary offering
12:00am
4
Saxe Jon S
20 Jun 19
DURECT / JON S SAXE ownership change
6:12pm
4
Neukermans Armand
20 Jun 19
DURECT / Armand Neukermans ownership change
6:11pm
4
Hoffmann Dave
20 Jun 19
DURECT / DAVE HOFFMANN ownership change
6:10pm